arrow
A

Anna-Lena Volckmar

national center for tumor diseases
H指数:34
被引数:3,537

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive Liquid Biopsy Testing in Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Patients: First Results from Routine Clinical Practice

转移性激素受体阳性HER2阴性乳腺癌患者中的全面液体活检检测:来自常规临床实践的首批结果

2026-05-010
PRE
Clinical Implementation of a High-Throughput Automated Comprehensive Genomic Profiling Test TruSight Oncology 500 HT
2025-02-010
OAAI
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations (vol 199, 113556, 2024)
2024-07-010
PRE
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
2024-03-014
OA
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors
2024-01-173
OAAI
First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
2023-01-124
OAAI
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
2022-07-2335
OA
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

EGFR-和ERBB2-mutated肺腺癌的免疫微环境

2021-10-0123
OAAI
Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine

将证据分配给可操作性: 精准癌症医学中的变异解释简介

2021-08-0916
OAAI